Primary Outcome Measures
Incidence of dose-limiting toxicities (DLTs) [Time Frame: From the start of treatment until the end of the DLT period (approximately 6 weeks for Arm A and B and 10 weeks for Arm C)] [Designated as safety issue: ]
Incidence of adverse events (AEs) and serious adverse events (SAEs) [Time Frame: From the start of treatment until the patient is off study (approximately 1 year for Arm A and C and approximately 7 weeks for Arm B)] [Designated as safety issue: ]
Secondary Outcome Measures
Event free survival (EFS) for Arms A and C only [Time Frame: From the start of treatment until the patient is off study (approximately 1 year)] [Designated as safety issue: ]
Objective response rate defined by RANO criteria for Arms A and C only [Time Frame: Every 8 weeks starting from 4 weeks after RT until the end of the study (approximately 1 year)] [Designated as safety issue: ]
Objective response rate defined by RANO-BM criteria for Arm B only [Time Frame: From screening until the patient is off study, approximately 8 weeks] [Designated as safety issue: ]
Objective response rate defined by RECIST 1.1 criteria for Arm B only [Time Frame: From screening until the patient is off study, approximately 8 weeks] [Designated as safety issue: ]
Maximum Observed Plasma Concentration (Cmax) of AZD1390 [Time Frame: At predefined intervals throughout the AZD1390 treatment period (approximately 5 weeks for Arms A and B and 9 weeks for Arm C)] [Designated as safety issue: ]
Time to observed Cmax (Tmax) for AZD1390 [Time Frame: At predefined intervals throughout the AZD1390 treatment period (approximately 5 weeks for Arms A and B and 9 weeks for Arm C)] [Designated as safety issue: ]
Area under the plasma concentration-time curve (AUC) for AZD1390 [Time Frame: At predefined intervals throughout the AZD1390 treatment period (approximately 5 weeks for Arms A and B and 9 weeks for Arm C)] [Designated as safety issue: ]
Renal clearance (CLR) for AZD1390 [Time Frame: At predefined intervals throughout the AZD1390 treatment period (approximately 5 weeks for Arms A and B and 9 weeks for Arm C)] [Designated as safety issue: ]